Crossmark

Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder

Crossref DOI link: https://doi.org/10.1186/s13722-024-00481-7

Published Online: 2024-07-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Freet, Christopher S.

Evans, Brianna

Brick, Timothy R.

Deneke, Erin

Wasserman, Emily J.

Ballard, Sarah M.

Stankoski, Dean M.

Kong, Lan

Raja-Khan, Nazia

Nyland, Jennifer E.

Arnold, Amy C.

Krishnamurthy, Venkatesh Basappa

Fernandez-Mendoza, Julio

Cleveland, H. Harrington

Scioli, Adam D.

Molchanow, Amanda

Messner, Amy E.

Ayaz, Hasan

Grigson, Patricia S.

Bunce, Scott C. https://orcid.org/0000-0002-1233-8709
Funding

Funding for this research was provided by:

National Institute on Drug Abuse (UG3DA050325)

Novo Nordisk (ISS-Drug)

Penn State Clinical and Translational Science Institute (UL1 TR002014)
License Information

Text and Data Mining valid from 2024-07-27

Version of Record valid from 2024-07-27
More Information

Article History

Received: 28 November 2023

Accepted: 7 June 2024

First Online: 27 July 2024

Declarations

:

: The study protocol, including the consent form, was approved by the Institutional Review Board of Penn State.

: Not applicable.

: Conflicts of Interest: SCB and HA own equity in fNIR devices, LLC (Potomac, MD). The authors report no other conflicts of interest.

Document is current

Any future updates will be listed below